UPDATES

$Tonix Pharmaceuticals (TNXP.US)$ On December 3, 2024, Tonix Pharmaceuticals announced the hiring of Bradley Raudabaugh as VP of Marketing and Errol Gould, Ph.D., as VP of Medical Affairs. This strategic expansion aims to support the launch of TNX-102 SL for fibromyalgia management.The company submitted a New Drug Application (NDA) for TNX-102 SL to the FDA in October 2024, with acceptance expected in December 2024. If approved, TNX-102 SL would be the first new fibromyalgia drug in over 15 years. An FDA decision is anticipated in August 2025.Tonix also updated its investor presentation and product candidate presentations for TNX-102 SL and TNX-1500, which are available on its website. The company continues to advance its CNS and immunology portfolios, including TNX-1300 and TNX-1500.